A collaborative effort between Fuzionaire Diagnostics [5], McGill University [6] and The Neuro (Montreal Neurological Institute-Hospital) [7] will foster the development of a new class of radioactive molecules — called radiochemicals — for the diagnosis and treatment of neurodegenerative diseases, including Parkinson’s disease [8].
Radiochemicals [9] are compounds prepared with radioactive elements that are used for medical applications, such as tracers in positron emission tomography [10] (PET) scans. PET scan is an imaging technique that uses small amounts of radioactive materials, a special camera and a computer to help detect emitted radiation and image biological function in vivo.